HDAC10 and its implications in Sézary syndrome pathogenesis

Area of Science:

• Hematology
• Dermatology
• Oncology
• Epigenetics

Background:

• Cutaneous T-cell lymphomas (CTCL) are rare skin cancers with Mycosis Fungoides (MF) and Sézary syndrome (SS) as main types.
• Sézary syndrome (SS) is an aggressive, incurable variant of CTCL with poor prognosis and treatment resistance.
• Epigenetic modifiers are implicated in CTCL pathogenesis, necessitating investigation into specific targets like HDAC10.

Purpose of the Study:

• To determine the role of Histone deacetylase 10 (HDAC10) in Sézary syndrome (SS).
• To investigate HDAC10's cellular localization, impact on cell growth, and therapeutic potential in SS.
• To explore HDAC10's involvement in SS pathogenesis and its association with critical cancer-related signaling pathways.

Main Methods:

• Analysis of HDAC10 expression and localization in SS patient samples.
• Assessment of HDAC10's effect on apoptosis, cell growth, and autophagy via knockdown experiments.
• Whole transcriptome analysis to identify HDAC10-associated signaling pathways.
• Evaluation of selective HDAC10 inhibition (HDAC10i) in combination with pro-apoptotic agents.

Main Results:

• HDAC10 is overexpressed in SS patients and predominantly localized in the cytoplasm.
• HDAC10 overexpression inhibits apoptosis and promotes cell growth; its knockdown reduces growth and induces apoptosis/autophagy.
• HDAC10 is linked to key cancer pathways (e.g., PI3K-Akt, Ras, MAPK, JAK-STAT) crucial for malignant T-cell survival.
• Selective HDAC10 inhibition enhances SS cell sensitivity to apoptosis-inducing drugs like Camptothecin (CPT).

Conclusions:

• HDAC10 plays a significant role in the molecular pathogenesis of Sézary syndrome (SS).
• HDAC10 is a potential therapeutic target for SS, as its inhibition impacts malignant T-cell survival and proliferation.
• Targeting HDAC10 may overcome treatment resistance in SS by enhancing apoptosis and reducing cell growth.